Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenumhomeobox-1 expression and increases endocrine cell mass in the pancreas ofold, glucose-intolerant rats

Glucose homeostasis in mammals is maintained by insulin secretion from the beta -cells of the islets of Langerhans. Type 2 diabetes results either fro m primary beta -cell failure alone and/or a failure to secrete enough insul in to overcome insulin resistance. Here, we show that continuous infusion o f glucagon-like peptide-1 (7-36) (GLP-1; an insulinotropic agent), to young and old animals, had effects on the beta -cell of the pancreas other than simply on the insulin secretory apparatus. Our previous studies on a rodent model of glucose intolerance, the aging Wistar rat, show that a plateau in islet size, insulin content, and beta -cell mass is reached at 13 months, despite a continuing increase in body weight. Continuous sc infusion of GLP -1 (1.5 pM/kg.min), over 5 days, resulted in normal glucose tolerance. Our current results in both young and old rats demonstrate that treatment cause d an up-regulation of pancreatic-duodenum homeobox-1 (PDX-1) expression in islets and total pancreas, induced pancreatic cell proliferation, and beta -cell neogenesis, The effects on levels of PDX-1 messenger RNA were abrogat ed by simultaneous infusion of Exendin (9-39), a specific antagonist of GLP -1. PDX-1 protein levels increased 4-fold in whole pancreata and 6-fold in islets in response to treatment. beta -cell mass increased to 7.2 +/- 0.58 from 4.88 +/- 0.38 mg, treated vs. control, respectively, P < 0.02. Total p ancreatic insulin content also increased from 0.55 +/- 0.02 to 1.32 +/- 0.1 1 <mu>g/mg total pancreatic protein. Therefore, GLP-1 would seem to be a un ique therapy that can stimulate pancreatic cell proliferation and beta -cel l differentiation in the pancreas of rodents.